Brookline Capital Management Predicts CervoMed Q3 Earnings

Key Points

• Brookline Capital Management has significantly reduced its Q3 2025 earnings per share (EPS) estimate for CervoMed to ($0.63), down from a previous forecast of ($0.34).
• CervoMed's stock has recently faced pressure, with shares dropping 6.9% and opening at $9.15 amid a market cap of $84.66 million.
• The consensus among analysts remains largely positive, with seven out of nine analysts rating the stock as a "buy" or better, indicating confidence in its prospects despite recent earnings setbacks.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Equities research analysts at Brookline Capital Management dropped their Q3 2025 earnings estimates for CervoMed in a research report issued on Monday, August 18th. Brookline Capital Management analyst T. Bussian now forecasts that the company will post earnings of ($0.63) per share for the quarter, down from their prior estimate of ($0.34). The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed's Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.65) EPS.

A number of other analysts have also issued reports on CRVO. Roth Capital restated a "buy" rating and issued a $16.00 price target (down previously from $20.00) on shares of CervoMed in a research note on Tuesday, August 12th. D. Boral Capital lifted their price target on shares of CervoMed from $15.00 to $31.00 and gave the stock a "buy" rating in a research note on Monday, August 18th. Chardan Capital restated a "buy" rating and issued a $15.00 price target on shares of CervoMed in a research note on Monday, August 11th. Finally, Canaccord Genuity Group lifted their price target on shares of CervoMed from $21.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, CervoMed presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.71.

CervoMed Price Performance

Shares of NASDAQ:CRVO traded up $0.39 during midday trading on Wednesday, reaching $9.52. The company had a trading volume of 55,605 shares, compared to its average volume of 2,009,455. The stock's fifty day moving average price is $7.92 and its 200-day moving average price is $7.48. The stock has a market capitalization of $88.06 million, a P/E ratio of -3.65 and a beta of -0.79. CervoMed has a one year low of $1.80 and a one year high of $20.63.

CervoMed (NASDAQ:CRVO - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). The company had revenue of $1.76 million during the quarter, compared to the consensus estimate of $1.45 million. CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.

Hedge Funds Weigh In On CervoMed

Several hedge funds and other institutional investors have recently modified their holdings of the company. AWM Investment Company Inc. acquired a new position in shares of CervoMed during the first quarter valued at $7,898,000. Woodline Partners LP acquired a new position in shares of CervoMed during the fourth quarter valued at $175,000. Jane Street Group LLC acquired a new position in shares of CervoMed during the second quarter valued at $414,000. Nuveen Asset Management LLC boosted its holdings in shares of CervoMed by 113.6% during the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock valued at $97,000 after acquiring an additional 22,104 shares during the period. Finally, Nuveen LLC acquired a new stake in CervoMed in the first quarter worth about $312,000. Institutional investors and hedge funds own 25.15% of the company's stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.